Loading…
Biotech developing FcRn-inhibitor antibodies for autoimmune diseases, competing in the same class as argenx's Vyvgart.
Biotech developing FcRn-inhibitor antibodies for autoimmune diseases, competing in the same class as argenx's Vyvgart.
Has no product to sell, so its costs are paid from money raised from investors; Roivant, the company that founded it, is the largest shareholder. Its value rests on clinical-trial results for IMVT-1402, which it has put ahead of batoclimab, before any route to market through approval and later sales.
Moat: narrow (IP / patents). A differentiated, potentially self-administered FcRn inhibitor competing against an already-approved class leader.
Headquarters: New York, New York, US · Founded: 2018 · Employees: 315
Size Immunovant (IMVT) is a United States Health Care company (Biotechnology) with a market value of $6.31B, the 1027th largest of 3,117 United States companies the cockpit tracks. Shares closed at $30.53 on 6 Nov 2026.
Performance Over six months the shares gained 5.5%, against -1.0% for the median peer and -1.1% for the United States market (cap-weighted) — 10th highest of 21 in its peer set.
Short interest Short interest is 8.8% of the free float (15 Oct 2026).
Next results Next results expected around 9 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$394,000 | -$409,000 | -$377,000 | -$231,000 | -$1.32M |
| EBITDA | -$566M | -$532M | -$438M | -$270M | -$207M |
| Net income | -$538M | -$506M | -$414M | -$259M | -$211M |
| Free cash flow | -$414M | -$407M | -$377M | -$215M | -$188M |
| Capital expenditure | $8,000 | $8,000 | $759,000 | $360,000 | $197,000 |
| Total debt | $0 | $72,000 | $98,000 | $138,000 | $1.57M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Immunovant IMVT | $6.31B | +5% | n/a | n/a | n/a | n/a |
| argenx SE Sponsored ADR ARGX | $57.5B | +19% | +71% | 29% | 10.0× | 10.9% |
| Johnson & Johnson JNJ | $665B | +26% | +8% | 26% | 7.0× | 3.5% |
| AstraZeneca AZN.L | $291B | +1% | +5% | 23% | 5.1× | 14.5% |
| Regeneron Pharmaceuticals REGN | $93.5B | +27% | +19% | 30% | 5.2× | -2.2% |
| Biohaven BHVN | $2.19B | +47% | n/a | n/a | n/a | n/a |
| Dianthus Therapeutics DNTH | $4.81B | -1% | -61% | -11,441% | 2,087.9× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | IMVT | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.9% | -2.8% | 9th highest of 21 |
| 6-month return | +5.5% | -1.0% | 10th highest of 21 |
| Distance from 52-week high | -32.8% | -30.0% | 9th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Immunovant IMVT | United States | $6.31B | +5% | n/a | n/a | n/a | n/a | n/a |
| Kodiak Sciences KOD | United States | $6.24B | +142% | n/a | n/a | n/a | n/a | n/a |
| CG Oncology CGON | United States | $6.74B | +9% | +1,030% | -4,056% | 917.8× | n/a | n/a |
| Scholar Rock SRRK | United States | $5.72B | -3% | n/a | n/a | n/a | n/a | n/a |
| Axsome Therapeutics AXSM | United States | $6.96B | -39% | +54% | -19% | 7.9× | n/a | n/a |
| Hangzhou Tigermed Consulting 3347.HK | Hong Kong | $5.65B | -1% | +22% | 10% | 5.6× | 28.3% | +15.6% |
| Caris Life Sciences CAI | United States | $7.13B | +56% | +85% | 15% | 6.9× | 18.7% | +85.4% |
| Cogent Biosciences COGT | United States | $5.49B | -9% | n/a | n/a | n/a | n/a | n/a |
| Anthem Biosciences ANTHEM.NS | India | $5.46B | +17% | -1% | 35% | 24.9× | 36.7% | +26.2% |
| Chongqing Zhifei Biological Products 300122.SZ | China | $5.35B | -2% | -28% | -210% | 5.4× | -6.4% | -10.0% |
| 10x Genomics TXG | United States | $7.72B | +174% | -4% | -14% | 11.8× | 41.8% | +16.6% |
| Twist Bioscience TWST | United States | $7.95B | +112% | +19% | -32% | 18.2× | n/a | n/a |
| 3SBio 1530.HK | Hong Kong | $4.92B | -34% | +102% | 61% | 1.2× | n/a | n/a |
| Edgewise Therapeutics EWTX | United States | $4.89B | +28% | n/a | n/a | n/a | n/a | n/a |
| Shanghai RAAS Blood Products 002252.SZ | China | $4.89B | -11% | -22% | 17% | 5.7× | n/a | n/a |
| CRISPR Therapeutics CRSP | United States | $4.86B | -9% | -34% | -2,059% | 133.6× | n/a | n/a |
| Arrowhead Pharmaceuticals ARWR | United States | $8.22B | -20% | +17% | -34% | 11.9× | n/a | n/a |
| Dianthus Therapeutics DNTH | United States | $4.81B | -1% | -61% | -11,441% | 2,087.9× | n/a | n/a |
| Beijing Wantai Biological Pharmacy Enterprise 603392.SS | China | $4.72B | -37% | +8% | -35% | 14.5× | n/a | n/a |
| Joinn Laboratories (China) 603127.SS | China | $4.58B | +15% | +12% | -4% | 15.1× | n/a | n/a |
| Genscript Biotech 1548.HK | Hong Kong | $8.81B | +96% | +53% | 12% | 9.9× | 36.5% | +19.8% |